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Abstract
In the last decades, advances that take place in the next-generation sequencing
and bioinformatics research have helped reveal tissue- and cancer-specific gene
expression patterns and mutation landscapes. Indeed, such data are now easily
accessible via online genome browsers and different types and levels of public data
compendia. Appropriate use of these tools eventually can lead to better patient
stratification for diagnosis, prognosis, and therapy of cancers. Mineralocorticoid
receptor (MR), encoded by NR3C2 gene, has long been implicated in the develop-
ment and progression of multiple cancers. Nevertheless, MR has remained rela-
tively understudied at the genomic and transcriptomic levels. In this review, we
present the current, literature-based state of knowledge on the role of MR primarily
in epithelial cancers. At the same time, we summarize the gene expression, muta-
tion, and copy number variation data on MR obtained from The Cancer Genome
Atlas (TCGA). We also show that MR expression could be a promising prognostic
marker in different cancers using online tools for survival data analysis. Accord-
ingly, this review strongly demonstrates the emerging potential of studying MR
using available tools from the genomics/transcriptomics field for improving cancer
diagnosis and prognostication.
Keywords: mineralocorticoid receptor, aldosterone, epithelial cancers, genomics,
transcriptomics, prognosis, The Cancer Genome Atlas, www.cbioportal.org
1. Introduction
MR/NR3C2 belongs to the steroid receptor family and it adopts important roles
in human physiology and pathology. Although MR has long been studied in renal
and cardiovascular contexts, identification of MR in multiple epithelial cancers and
presence of cross talk between steroid receptors in cancer-related processes make
MR a promising candidate for cancer diagnosis and prognosis. Nevertheless, a
focused yet comprehensive literature review about MR’s expression in cancers and
established role in cancer-associated hallmarks is lacking. Our literature search
reveals that MR is expressed in cancerous as well as adjacent and/or normal tissue
although the expression of MR can become deregulated during cancer development.
Moreover, we provide an account of changes in ligand-dependent or -independent
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MR signaling in association with cell proliferation, apoptosis, and senescence of
cancer cells. We also identify future directions that can help target novel aspects of
MR signaling for mechanistic studies as well as cancer therapeutics. In addition, we
point out an emergent need for analyzing the range of genomic alterations and
variability in MR expression and its potential association with prognosis across
epithelial solid tumors using the existing genomic and transcriptomic resources. We
exemplify the extent of variability in MR expression within and among patients
based on the patient data found in The Cancer Genome Atlas (TCGA) [1]. More-
over, we demonstrate the profound potential of MR expression as a biomarker for
cancer prognostication, i.e., estimation of the likelihood of developing future risks
for cancer over a time period using TCGA datasets [2].
2. A concise literature review on MR in cancer biology
Herein an overview of the scientific literature on MR is provided using examples
mainly from cancers of epithelial origin including the lung, colon, liver, kidney,
pancreas, prostate, breast, and adrenal gland, revealing the understudied aspects of
MR in the context of cancer biology.
2.1 Lung cancer
The presence of MR protein in lung cancer tissues has opened new avenues for
MR research. Suzuki et al. [3] demonstrated by immunohistochemistry (IHC) that
primary lung cancer tissues expressed MR protein along with HSD11B2 enzyme,
required for MR receptor specificity through conversion of cortisol to cortisone.
However, MR and HSD11B2 proteins, although present and significantly correlated
with each other in lung adenocarcinomas, were non-existent in squamous cell, small
cell, or large-cell carcinomas [3]. Next, Jeong and colleagues [4] studied gene
expression signatures of all 48 nuclear receptors (NRs) including MR in non-small-
cell lung cancers (NSCLCs) and corresponding normal lung tissues and found that
short heterodimer partner (SHP) and progesterone receptor (PGR) predicted sur-
vival in patients with early-stage lung tumors. In the same study, the prognostic role
of NRs was also investigated in corresponding normal tissues; and higher expres-
sions of MR and nerve growth factor-induced gene B3, NGFIB3, were identified as
predictors of good prognosis for survival and disease recurrence [4]. Furthermore,
increasing aldosterone levels in the presence of VEGF inhibitors also proved to be a
better indicator of prognosis in NSCLC patients [5]. However, future epidemiolog-
ical as well as mechanistic studies are needed to address the cross talk between
antiangiogenic drugs and MR signaling in lung cancer.
2.2 Colorectal cancer
In colon cancer, an observed decrease in the expression of MR in cancerous
tissue in comparison to the adjacent normal mucosa has attributed MR a tumor
suppressive role [6]. Tiberio et al. [7] further investigated how MR expression
correlated with patient survival in colorectal carcinomas. In this study, the expres-
sions of MR and tumor microvessel density marker protein CD34 were evaluated in
tumor and normal colorectal mucosa by IHC, and an inverse correlation of expres-
sion was detected between them in colorectal cancers. Kaplan–Meier survival anal-
ysis has led to a conclusion that MR could be a tumor suppressor whose decreased
expression is correlating well with poor patient survival based on a relatively small
number of patients [7]. Recently, spironolactone, an MR antagonist, has also arisen
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as a tumor suppressor in colon carcinoma yet independent of MR and through RXRγ
receptor signaling [8]. Moreover, recent studies showed that HSD11B2 inhibition,
and hence potential dysregulation of MR signaling, could modify gut microbiota,
known to be an important factor in colon carcinogenesis [9]. A better understand-
ing of MR cross talk with other nuclear receptors and interaction with gut
microbiota from patients treated with MR antagonists is needed in the future.
2.3 Breast cancer
MR expression in normal and diseased breast tissues was initially identified in
the 1990s [10, 11]. MR and HSD11B2 proteins were shown to co-localize predomi-
nantly in the duct epithelia and to exhibit higher expressions in invasive ductal
carcinoma than invasive lobular carcinoma [11]. More recently a study by Conde
et al. [12] found that MR expression was peculiar to the cytoplasm of benign and
cancerous breast lesions, whereas GR/NR3C1 expression was nuclear in benign
breast lesions but showed cytoplasmic as well as nuclear distribution in cancer
tissues. These findings might suggest a potential deregulation of GR signaling in
malignant tissues, while the effects of MR on tumor development could be less
ligand-dependent and/or ligand-insensitive in breast cancer. However, this remains
to be assessed.
Induction of growth of lobulo-alveolar structures in mouse mammary gland by
MR ligand aldosterone also pointed to the importance of MR signaling in breast
biology [13–15]. Furthermore, the presence of progesterone, a potential MR ligand,
in the breast tissue highlighted the significance of MR in breast cancers [16]. In
addition, in vitro culturing of breast cancer cell lines provided further opportunities
for understanding the impact of MR signaling in tumor growth. For example, in the
breast cancer cell line PMC42 with detectable MR and HSD11B2 expression levels,
aldosterone, alone, did not have an effect on cell proliferation yet when given
together with the anti-mineralocorticoid spironolactone resulted in a significant
decrease in cell numbers [17]. In another study, aldosterone and cortisol exerted
progesterone-like effects such as induction of focal adhesion and reduced cell
growth in the progesterone receptor-transfected MDA-MB-231 breast cancer cell
line [18]. Recently, genomic and non-genomic actions of aldosterone through
G-coupled estrogen receptor (GPER) and MR signaling pathways were demon-
strated [19]. Rapid aldosterone exposure activated EGFR and ERK1/2 transduction
pathway through MR and GPER in the HER2+ breast cancer cell line SkBr3 and
breast tumor-derived endothelial cells [19]. Furthermore, direct interactions among
GPER and MR as well as GPER and EGFR were shown, while a long-term exposure
to aldosterone increased cell growth which could be inhibited by the silencing of
MR expression [19]. These findings indicated possible contributions of GPER activ-
ity in the MR-dependent aldosterone signaling and EGFR activation in the regula-
tion of cancer cell growth. However, the relationship between aldosterone and other
modulators of GPER, e.g., estrogen, remains to be investigated in breast cancer. MR
receptors can exhibit affinity to aldosterone and cortisol as well as other potential
ligands likely to be found in the milieu of breast cancer, and thus studying MR, GR,
GPER, and/or other receptor crosstalk could be important for better evaluating
mammary gland physiology and pathology.
2.4 Liver cancer
As in the lung and colon cancers, MR expression was shown to be downregulated
in a large cohort of liver cancer patient tissues [20]. Furthermore, in the same study,
overexpression of MR suppressed cancer progression by inhibition of proliferation
3
Investigating the Role of Mineralocorticoid Receptor Signaling in Cancer Biology in the Genomic…
DOI: http://dx.doi.org/10.5772/intechopen.87233
and induction of cell cycle arrest eventually leading to apoptosis. Aldosterone’s
effect on tumor growth was also tested, and its antiproliferative and apoptotic
effects were reversed by spironolactone. All of these significantly implicated an
evidence for decreased MR signaling in liver cancer pathogenesis [20]. Additionally,
this study showed that MR suppressed the Warburg effect [20] by which cancer
cells gain growth advantage over normal cells [21] leading to novel insights about
MR signaling through cancer research.
Apart from cancer, fibrosis is another significant pathology of the liver. Fibrosis,
the leading factor of liver carcinogenesis, occurs due to the accumulation of
fibrogenic cells and extracellular matrix (ECM) proteins in excess [22, 23]. ECM is
central to sustain cellular homeostasis and integrity, and deregulation of ECM is
considered as a hallmark of cancer [24]. The role of aldosterone on ECM synthesis
and potentially on liver fibrosis was previously shown in rats, although independent
of MR itself [25]. On the other hand, spironolactone was shown to act as a potent
provocateur of liver regeneration following partial hepatectomy [26]. As a result,
these studies demonstrate the current need for better understanding the role of
ligand-dependent and ligand-independent signaling of MR in different facets of
liver pathologies including fibrosis, regeneration, and carcinoma.
2.5 Renal cancer
MR and aldosterone signaling have been extensively studied in kidney physiol-
ogy and pathology for decades [27, 28] and to some degree, in renal carcinomas.
Initially, the protein expressions of MR and HSD11B2 were characterized in a large
cohort of renal cell neoplasms of different cellular origins using IHC. In this study,
co-expression HSD11B2 and MR was shown in normal distal nephron, in chromo-
phobe renal cell carcinoma (chRCC) and oncocytoma of distal nephron origin [29].
In renal cell carcinoma, aldosterone led to upregulation of KRAS oncogene
(KRAS4A splice variant) resulting in increased survival and cell proliferation [30].
Yet another study revealed that aldosterone exerted its migratory/metastatic actions
through G-protein-coupled estrogen receptor (GPER) in a murine renal cortical
adenocarcinoma cell line and also in mice in vivo [31]. These findings implicated
important oncogenic pathways and their crosstalk with MR and aldosterone signal-
ing in renal cancers.
Hypertension is a well-established risk factor in kidney cancers potentially due
to the genotoxic nature of aldosterone [32, 33]. Indeed, supraphysiological levels of
aldosterone treatment induced DNA breaks and chromosomal aberrations in epi-
thelial porcine kidney cells, whereas MR blockade by antagonists prevented forma-
tion of such aberrations [34]. Genotoxic effects of aldosterone were investigated
further in the DOCA-salt-treated rat model used for inducing MR-dependent
hypertension. DOCA-salt treatment caused inflammation, oxidative stress, DNA
damage, and increased kidney cell proliferation [35]. Another study highlighted
aldosterone-dependent induction of oxidative stress and DNA damage as well as
activation of MR-dependent NFKB signaling pathway in kidney tubule cells [36].
Queisser et al. [37] further addressed the downstream signaling pathways triggered
by aldosterone-induced oxidative stress both in vitro (porcine kidney cells with
proximal tubular properties) and in vivo (rat kidneys). In these models, aldosterone
treatment resulted in MR-dependent activation of ERK1/2 and its target, STAT3;
and hence aldosterone exposure led to higher proliferation rates while diminishing
apoptosis [37]. Accordingly, the role of aldosterone-induced MR signaling in dereg-
ulation of DNA damage response needs to be studied also in other epithelial cancers
in more detail.
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Senescence, evasion of which is another hallmark of cancer [38], was studied in
the context of aldosterone signaling in different renal models. For example,
p16INK4a, a cyclin-dependent kinase inhibitor and a cellular senescence marker
[39, 40], was induced in the kidneys and hearts of DOCA-salt-treated rats [41].
These effects could be reversed by antihypertensives and spironolactone,
suggesting a potential role of MR signaling in the regulation of the senescent phe-
notype [41]. In another study, senescence was investigated in aldosterone-infused
rats and cultured human proximal tubular cells. In both models, aldosterone-
induced senescence-like characteristics were marked by senescence-associated
beta-galactosidase staining, p21/Cdkn1a and p53 overexpression, and SIRT1
under-expression. MR blockade either using eplerenone (in vivo) or through gene
silencing (in vitro) sufficiently reversed the aldosterone-induced senescence-like
characteristics [42]. In line with this study, Kitada et al. [43] also showed the
presence of aldosterone-induced senescence, characterized by increased p21
expression and beta-galactosidase staining, in human proximal tubular cells.
Furthermore, a prolonged exposure to aldosterone triggered p21-mediated cytokine
release, e.g., TNF alpha, which in turn led to apoptosis [43]. All of these have
implicated MR signaling through interaction with aldosterone in the induction of
senescence, an inherent autoregulatory mechanism of proliferating cells with
established tumor suppressive activity. The role of MR/aldosterone-induced
senescence in epithelial cancers however needs to be further studied since this can
provide an effective route for therapeutic invention.
2.6 Pancreas cancer
Recently, MR has been ascribed a tumor suppressive role also in pancreatic
ductal adenocarcinoma (PDAC) [44]. In PDAC patients, dysregulated expression of
macrophage migration inhibitory factor (MIF) was associated with disease aggres-
siveness, and MIF-driven upregulation of miR-301b was shown to suppress MR
expression [44]. In turn, MR expression resulted in the inhibition of epithelial to
mesenchymal transition (EMT) and increased chemotherapeutic drug
(gemcitabine) sensitivity. Consistently, survival data analysis further associated
downregulation of MR expression with poor survival in PDAC patients [44]. How-
ever, PDAC remains one of the cancers receiving less attention in the MR field;
future studies can address the role of genomic and non-genomic effects of MR
signaling in PDAC.
2.7 Prostate cancer
Detection of 11 beta-hydroxysteroid dehydrogenase enzyme [45] and a func-
tional MR in the androgen-dependent prostate cancer cell line LNCaP cells dates
back to the early 1990s [46]. More recently, Dovio et al. [47] assessed GR and MR
expression together with HSD11B-1 and HSD11B-2 enzyme activity upon inflam-
matory stimulus (IL1B stimulation) or basal conditions in the androgen-dependent
and androgen-independent prostate cancer cell lines. Diverse expression patterns of
MR, GR, and HSD11B enzyme activities were detected among cell lines, while
downstream effects of IL1B exposure were inhibited by cortisol or dexamethasone
in a cell line-dependent manner [47].
Another lead for the role of mineralocorticoids in prostate cancer has come from
abiraterone acetate (AA), an androgen synthesis inhibitor, used for metastatic
castration-resistant prostate cancer (mCRPC), which results in secondary mineral-
ocorticoid excess [48]. Androgen-induced conformational changes in androgen
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receptor (AR) could be inhibited in the presence of mineralocorticoids (corticoste-
rone or deoxycorticosterone). However, administration of corticosterone alone
resulted in repression of AR transcriptional activity and cellular growth at concen-
trations present in the serum of AA-administered patients [49]. Pia et al. [50]
focusing on identifying ways of eliminating adrenocorticotropic hormone (ACTH)-
dependent AA-induced mineralocorticoid excess showed that a low effective dose
of glucocorticoid together with MR antagonist and salt deprivation could be an ideal
treatment. Indeed, the use of prednisone, a synthetic glucocorticoid, could over-
come the effects of secondary mineralocorticoid excess in mCRPC patients treated
with abiraterone [51]. Effect of eplerenone-abiraterone co-administration on sec-
ondary mineralocorticoid excess syndrome and progression-free survival (PFS) was
evaluated and compared to prednisone-abiraterone co-administered in patients. No
significant difference was obtained by means of mineralocorticoid excess syndrome
characteristics and PFS between these two experimental groups; and this has raised
AA-eplerenone as an alternative therapy for overcoming prednisone-induced side
effects [52]. Enzalutamide is another antiandrogen drug used for treating metastatic
prostate cancer patients; however, resistance gained against enzalutamide therapy
remains a challenge. GR signaling induces antiandrogen resistance by hijacking AR
function [53, 54]; hence, the therapeutic effects of enzalutamide-corticosteroid co-
administration were addressed in prostate cancer cells [55]. Dexamethasone
decreased the therapeutic effects of enzalutamide as well as increasing resistance.
However, prednisolone and aldosterone diminished resistance to enzalutamide.
Consistently, silencing of MR resulted in enhanced resistance to enzalutamide and
AR activity [55]. Moreover, the effects of diverse antihypertensive medication on
prostate cancer survival following radical prostatectomy were tested in the Finnish
population, and overall, the antihypertensive treatment was associated with
increased death risk [56]. These findings clearly establish the importance of AR and
MR cross talk and complex ligand interactions in prostate cancer, which could be
further studied in other cancers and cancer subtypes where AR signaling can
play a role.
2.8 Adrenocortical cancer
Adrenal incidentalomas include adrenocortical adenomas, adrenocortical carci-
nomas, and pheochromocytoma [57, 58]. Aldosterone-producing adenomas (APA,
i.e., benign tumors of the adrenal glands) account for 35% of the diseases of the
primary aldosteronism spectrum [59, 60]. Somatic mutations occurring in KCNJ5,
CACNA1D, ATP1A1, ATP2B3, and CTNNB1 genes give rise to sporadic APA [61].
In addition to the abovementioned mutations, regulatory RNAs such as miRNAs
have also been shown to be important in modulating aldosterone levels and tumor-
igenesis [62–64]. On the other hand, adrenocortical cancers (ACC), some of which
are hormone-producing, occur relatively rarely, and patients with ACC exhibit
poor prognosis with a median survival of 5.5 years [65]. In the adrenocortical cell
line H295R, aldosterone in vitro is shown to upregulate T-type calcium channel
expression and currents, an effect reversed by spironolactone [66]. H295R cells
have also been shown to express components of aldosterone signaling pathway
including ENaC subunits, NEDD4L, SGK1, MR, and HSD11B2 [66, 67]. Although
several factors, such as age, resection margin and proliferation scores, uterine
steroid profiles, CpG island hypermethylation status, as well as levels of selected
biomarkers, have been tested for their contribution in ACC prognosis, the impor-
tance of MR expression status is yet to be evaluated in ACC patients [65, 68, 69].
Future studies should investigate the role of activation/inactivation of
MR-aldosterone signaling in diagnosis/prognosis of ACC for which significant
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amounts of genomic and transcriptomic data have recently become available
(please see the next section for details).
3. Cancer genome and transcriptome analyses for MR using online tools
The advent of whole-genome sequencing and development and availability of
genome browsers, such as UCSC genome browser [70, 71] and Ensembl [72, 73], in
the early 2000s have enabled researchers to identify genes/genomic intervals that
are important in human physiology and pathology. This is mainly done by associa-
tion of genome fragments with informative tracks that range from expression
values to the presence of copy number and single nucleotide variations (CNVs and
SNVs, respectively). Cataloging and annotation of the human genome with regard
to genomic and transcriptomic variation have also revolutionized cancer research
[74, 75]. The NIH-driven giant effort named The Cancer Genome Atlas (TCGA) has
published its first results in 2008 on the genomic and transcriptomic landscape of
gliomas [76]. Over the years, TCGA has expanded to house thousands of cancer
genomes/transcriptomes/proteomes from tens of different cancers allowing
researchers from all over the world to have unlimited access to cancer-related
datasets [1]. Many different web-based tools nowadays use TCGA and Catalog of
Somatic Mutations in Cancer (COSMIC) [77] as primary resources and build on
them to extract data from user-provided queries and/or to perform gene-specific or
genome-wide secondary analyses, such as cbioportal.org [78, 79]. These webservers
make use of a wide range of information and incorporate quantitative and statistical
analyses and visualization tools and help users with little or no programming expe-
rience perform cancer bioinformatics analyses.
The expression of MR along with those of other nuclear receptors has been
studied in a recent TCGA PanCancer transcriptomics study of bladder, breast,
colon, head and neck, liver, and prostate cancers; and MR expression is shown to be
downregulated in all [80]. To demonstrate the potential of TCGA in revealing the
importance of MR in cancer research, we have used www.cbioportal.org webserver
[78, 79] to visualize the next-generation RNA sequencing data from different can-
cers of TCGA provisional datasets for MR and showed that MR mRNA is expressed
differentially across many tumor types (Figure 1). Among these, chromophobe
renal cell carcinoma (chRCC) has the highest expression of MR followed by thyroid
carcinoma (THCA), pheochromocytoma and paragangliomas (PCPG), and adreno-
cortical carcinoma (ACC), while carcinomas of the bladder, breast, cervix, esopha-
gus, head, and neck exhibit high variability (Figure 1). It is also apparent that
genomic alterations (gains and shallow deletions) are common in many of these
TCGA dataset patients (Figure 1). Future analyses can focus on how these alter-
ations are associated with MR expression in different cancers, especially in
chRCC and ACC.
Overall, the observed rate of somatic mutations of MR has been shown to be
significantly lower with respect to the expected rate suggesting MR does not toler-
ate well mutations with functional constraints [81]. On the other hand, functional
mutations of MR have been identified in different contexts including renal
pseudohypoaldosteronism as well as hypertension [81, 82]. In addition, relatively
different residues in the DNA-binding domain of MR seem to be affected between
type I pseudohypoaldosteronism and cancers [83]. Herein we have compiled the
MRmutation landscape for cancers found in TCGA provisional datasets (cbioportal.
org) showing the number (95 missense, 19 truncating totaling 0.9% somatic muta-
tion frequency) as well as the distribution of mutations across the MR protein
sequence (984 amino acids long) and the DNA-binding domain zinc finger, C4 type
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(zf-C4; 602–669), and ligand-binding domain of NR (753–934) (Figure 2A). How-
ever, it is important to note that TCGA datasets are dynamic in nature such that
new samples as well as mutation/CNV annotations are continually being added.
www.cbioportal.org webserver also offers two separate and large multi-cancer
Figure 2.
Mutation landscape and distribution of genetic alterations in MR. (a) Schema showing the location of MR
mutations and the two functional domains of MR. (b) The bar graph showing the percentages of mutations,
amplifications, and deletions in TCGA provisional datasets. Source: cbioportal.org.
Figure 1.
Boxplots of MR/NR3C2 expression across different TCGA provisional datasets obtained from cbioportal.org.
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collections, i.e., TCGA PanCancer and curated TCGA/non-TCGA (curated set of
non-redundant) datasets. Upon analysis of these two collections, the numbers of
observed missense mutations in the MR gene increase to 193 and 281, and truncat-
ing mutations to 34 and 48, respectively. It is also possible to download functional
annotations for these mutations that include scores showing the impact of muta-
tions, e.g., analyzed through MutationAssessor.org [84, 85]. Accordingly, in the
curated TCGA/non-TCGA dataset collection, we have identified, among all 334
mutations, 6 high-impact mutations, all of which are located in the zf-C4 domain
(Table 1). Functional analysis of MR mutation landscape thus can help researchers
select high-impact variants for future validation studies using MutationAssessor
as well as other tools linked with www.cbioportal.org, e.g., SIFT [86] and
PolyPhen-2 [87].
Moreover, using TCGA provisional datasets, we analyzed whether MR accumu-
lated different rates of genetic alterations in different cancers (Figure 2B). The
mean proportion of genetic alterations per cancer was 0.024 (0.017–0.031, 95%
confidence interval, CI). The results in percentages showed that around 7% of
uterine carcinosarcoma patients exhibited genomic alterations (mutation, amplifi-
cation; 7.02% in 57 cases), while the second and third ranking cancers were those of
esophageal carcinoma (5.38% in 186 cases) and stomach adenocarcinomas (5.23% in
478 cases) (Figure 2B). As mentioned above the ranking of these cancers in terms
of percent genomic alterations can be dynamic depending on which data collection
has been used. For example, when using TCGA PanCancer sample collection, which
reports a more complete mutation/CNV annotation information, the first ranking
cancer with the highest percentage of genetic alterations has become melanoma
(8.71% out of 448 skin cutaneous melanoma) followed by uterine carcinomas
(7.75% out of 529 uterine corpus endometrial carcinoma and 7.02% out of 57 uterine
carcinosarcomas). Future studies may focus on uterine carcinomas and melanoma
to address the mechanisms and effects of these observed alterations.
4. Investigating the role of MR in cancer patient stratification and
prognosis using genomics resources
Survival analysis is often used for studying the association of an event of inter-
est, e.g., death and disease recurrence, with another clinical or biological variable
[88]. Analysis of TCGA-associated survival data (overall survival (OS) and/or
relapse-free survival (RFS)) is available through several online webservers includ-
ing GEPIA [89], OncoLnc [90], Kaplan–Meier Plotter [91], and KM-Express [92].
These tools help evaluate survival of cancer patients whose genomic/transcriptomic
and clinical data are stored in TCGA, by using Cox coefficient statistics, hazard ratio
(HR) and/or logrank tests, and Kaplan–Meier plots. GEPIA, which has previously
Table 1.
High-impact MR mutations based on MutationAssessor in curated TCGA and non-TCGA dataset collection
(www.cbioportal.org).
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been used in prognostic identification of several biomarkers in ACC [93, 94], per-
forms survival statistics in addition to providing other functionalities such as co-
expression analysis and diagnostic marker prediction. We analyzed data from all
cancers available in GEPIA and showed that an NR3C2/MR expression higher than
the median level predicted a significantly better prognosis (OS) and low HR in
adrenocortical carcinoma (ACC), kidney renal clear cell carcinoma (KIRC), breast
invasive carcinoma (BRCA), colon adenocarcinoma (COAD), brain lower-grade
glioma (LGG), and liver hepatocellular carcinoma (LIHC) (logrank p-value <0.1;
Figure 3).
Figure 3.
MR expression-based overall survival (OS) analyses performed using GEPIA. Adrenocortical carcinoma
(ACC), breast invasive carcinoma (BRCA), colorectal adenocarcinoma (COAD), kidney renal clear cell
carcinoma, low-grade glioma (LGG), and liver hepatocellular carcinoma (LIHC). The statistics and their
associated p-values are shown on graphs, while groups (red and blue) are separated by the median expression
level of MR.
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Similar analyses can be performed using other webservers, such as KM plotter
(http://kmplot.com/analysis/), which allows for auto-selection of an expression
threshold that performs best in the logrank test. Recently, KM plotter has also made
possible the stratification of TCGA PanCancer patient data according to different
clinical and demographic variables including gender [95]. For example, we tested
the significance of association between MR expression and OS using the best
cutoff option separately for females and males, in renal cancers, KIRC and KIRP.
Accordingly, we found that sexual dimorphism in MR expression can play a role in
association with OS, warranting further investigation (Figure 4). Importantly, it is
also possible to study MR expression and its role in RFS using the same tools. Our
findings through GEPIA and KM plotter help confirm that downregulation of MR/
NR3C2 expression can be significantly associated with cancer progress as has been
previously reported in the literature. In conclusion, large-scale expression analysis
in association with clinical data such as time to death or recurrence can thus reveal
the importance of MR expression in epithelial and other solid tumors yet warrants
further mechanistic studies.
5. Conclusion
A comprehensive look at the history of MR in cancer research strongly impli-
cates the dysregulation of MR signaling in the development and progression of
epithelial cancers. However, the interactions with its natural ligand aldosterone
and/or with other potential ligands, such as tissue-specific progesterone as well as
the growing evidence on the presence of receptor cross talk, complicate the “tumor
suppressive” role often attributed to MR. MR’s relatively well-established effects in
renal tissue senescence, oxidative stress and DNA damage, as well as its emerging
Figure 4.
KM plotter analysis of kidney renal clear cell carcinoma (KIRC) and kidney renal papillary cell carcinoma
(KIRP) for all, female and male patients, separately.
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potential in the regulation of Warburg effect and fibrosis/regeneration in liver
tissue represent novel avenues to pursue especially in the context of cancer therapy.
In addition, the genome-wide availability of CNV, SNV, and mRNA expression
profiles from cancer patients enables comparisons within and between different
tumors providing an enhanced level of accessibility to researchers in the field of
cancer biology. Indeed, online examination of the interaction between different
data sources such as expression and patient survival data is now effectively possible
for MR and can be extended to other genes participating in MR signaling. Genera-
tion of large-scale genome-wide data along with the development of tools that help
analyze and integrate such data is likely to further enhance our understanding of
MR in the development and progression of different cancers.
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